Business
Press Release: Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season
Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season First study showing that infants immunized against RSV in their first season had fewer RSV hospitalizations in their second season The study also showed a reduction of 85.9% in RSV-related lower respiratory tract infection hospitalizations in the first season Data published in The Lancet Infectious Diseases and to be presented at RSVVW ’26 conference in Rome Paris, February 16, 2026. A u
About this update from Sanofi Sa
[{"type":"image","alt":"Sanofi Winthrop Industrie","displaySize":"","headline":null,"caption":"Sanofi Winthrop Industrie","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":84,"url":"https://media.zenfs.com/en/globenewswire.com/c45c40f5ed741dd9c0f5c2f75b8fc137"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/njIuMc8eT.GfUOY8hGPCUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c45c40f5ed741dd9c0f5c2f75b8fc137","width":300,"height":84}},"lazy":false},{"type":"text","content":"Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season ","length":109,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"First study showing that infants immunized against RSV in their first season had fewer RSV hospitalizations in their second season","length":130,"tagName":"p"}]},{"val":[{"type":"text","content":"The study also showed a reduction of 85.9% in RSV-related lower respiratory tract infection hospitalizations in the first season","length":133,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":263,"olType":false},{"type":"text","content":"Data published in The Lancet Infectious Diseases and to be presented at RSVVW ’26 conference in Rome","length":100,"tagName":"p"},{"type":"text","content":"Paris, February 16, 2026. A universal respiratory syncytial virus (RSV) immunization program using Beyfortus (nirsevimab) was associated with a statistically significant reduction in RSV-related hospitalizations in the second RSV season among infants immunized during their first season, according to a new study published in The Lancet Infectious Diseases. The NIRSE-GAL study, conducted in Galicia, Spain, is the first prospective real-world population study to evaluate the impact of a universal Beyfortus immunization program during two consecutive RSV seasons. The study findings, comparing the number of hospitalizations in immunized infants during their second RSV season versus the number of expected hospitalization cases based on data from recent seasons, are being presented at RSVVW ’26 (Respiratory Syncytial Virus Vaccines for the Word) conference in Rome, Italy.","length":882,"tagName":"p"},{"type":"text","content":"The coverage rate was 94.4% among the cohort (11,796 infants out of 12,492 eligib...